NPPB and chronic obstructive pulmonary disease: This study underscores the clinical utility of age- and comorbidities-adjusted NT-proBNP as a low-cost, accessible biomarker to screen for the identification of cardiac involvement and HF risk in older patients with GOLD E COPD.